[go: up one dir, main page]

NO20090292L - Fenyleddiksyrederivater - Google Patents

Fenyleddiksyrederivater

Info

Publication number
NO20090292L
NO20090292L NO20090292A NO20090292A NO20090292L NO 20090292 L NO20090292 L NO 20090292L NO 20090292 A NO20090292 A NO 20090292A NO 20090292 A NO20090292 A NO 20090292A NO 20090292 L NO20090292 L NO 20090292L
Authority
NO
Norway
Prior art keywords
phenylacetic
pharmaceutically acceptable
cox
compounds
useful
Prior art date
Application number
NO20090292A
Other languages
English (en)
Inventor
Lauren G Monovich
Benjamin Biro Mugrage
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090292(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20090292L publication Critical patent/NO20090292L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02—Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelser med formel (I), farmasøytisk akseptable salter av disse; og farmasøytisk akseptable estere av disse; som er nyttige i behandlingen av COX-2 avhengige forstyrrelser.
NO20090292A 2006-06-26 2009-01-19 Fenyleddiksyrederivater NO20090292L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80578406P 2006-06-26 2006-06-26
PCT/US2007/071979 WO2008002853A2 (en) 2006-06-26 2007-06-25 Phenylacetic acid derivatives as cox-2 inhibitors

Publications (1)

Publication Number Publication Date
NO20090292L true NO20090292L (no) 2009-01-26

Family

ID=38667003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090292A NO20090292L (no) 2006-06-26 2009-01-19 Fenyleddiksyrederivater

Country Status (27)

Country Link
US (3) US8362294B2 (no)
EP (1) EP2046723B1 (no)
JP (1) JP5258761B2 (no)
KR (1) KR101380423B1 (no)
CN (1) CN101479231A (no)
AR (2) AR061623A1 (no)
AU (1) AU2007265181B2 (no)
BR (1) BRPI0713523A8 (no)
CA (1) CA2655676C (no)
CL (1) CL2007001857A1 (no)
CR (1) CR10506A (no)
EC (1) ECSP088988A (no)
ES (1) ES2386989T3 (no)
GT (1) GT200800296A (no)
IL (1) IL195958A (no)
MA (1) MA30567B1 (no)
MX (1) MX2008016337A (no)
MY (1) MY145122A (no)
NO (1) NO20090292L (no)
PE (1) PE20080213A1 (no)
PL (1) PL2046723T3 (no)
PT (1) PT2046723E (no)
RU (1) RU2454402C2 (no)
TN (1) TNSN08531A1 (no)
TW (1) TW200817309A (no)
WO (1) WO2008002853A2 (no)
ZA (1) ZA200810562B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156809B2 (en) 1999-12-17 2007-01-02 Q-Tec Systems Llc Method and apparatus for health and disease management combining patient data monitoring with wireless internet connectivity
CN102781235B (zh) 2010-02-19 2015-04-22 拜耳知识产权有限责任公司 3-氨基羰基-取代的苯甲酰环己二酮和它们作为除草剂的用途
JP6250893B2 (ja) * 2015-02-13 2017-12-20 トヨタ自動車株式会社 ブローバイガス処理装置およびインテークマニホールド
CN105669732B (zh) * 2016-01-10 2017-05-31 沧州普瑞东方科技有限公司 一种合成4‑氟‑5‑异丙基‑2‑甲氧基苯硼酸的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133740C (no) 1965-04-08
DK125461B (da) 1967-12-20 1973-02-26 Ciba Geigy Ag Fremgangsmåde til fremstilling af substituerede phenyleddikesyrer eller salte deraf.
JPS51149252A (en) 1975-06-14 1976-12-22 Ikeda Mohandou:Kk A process for preparing naphthylaminophenyl acetic acid derivatives
US4001878A (en) 1975-11-19 1977-01-04 Rca Corporation Charge transfer color imagers
JPS5268159A (en) 1975-12-03 1977-06-06 Ikeda Mohando Co Production of naphthyl aminophenyl acetic acid derivatives
JPS5283822A (en) 1976-01-01 1977-07-13 Ikeda Mohando Co Naphthylaminopheny acetic acid derivatives and salts thereof*
JPS5770848A (en) * 1980-10-20 1982-05-01 Zenyaku Kogyo Kk Preparation of o-substituted phenylacetic acid
CH650766A5 (en) 1980-10-20 1985-08-15 Zenyaku Kogyo Kk Process for preparing o-(2,6-Dichloroanilino)phenylacetic acid
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US6355680B1 (en) * 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
PL352294A1 (en) 1999-06-10 2003-08-11 Warner Lambert Co Method of inhibiting amyloid proteins aggregation and of visualising amyloid concretions with the use of isoindolyne derivatives
GB9922830D0 (en) 1999-09-27 1999-11-24 Novartis Ag Processes
WO2003020268A1 (en) 2001-08-31 2003-03-13 Washington University Method for the treatment and prevention of cachexia
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
WO2005033200A1 (ja) 2003-10-01 2005-04-14 Polyplastics Co., Ltd. ポリアセタール樹脂組成物
CN101889333B (zh) 2007-12-17 2012-08-08 日矿金属株式会社 基板和其制造方法

Also Published As

Publication number Publication date
WO2008002853A2 (en) 2008-01-03
TNSN08531A1 (en) 2010-04-14
CA2655676A1 (en) 2008-01-03
KR101380423B1 (ko) 2014-04-01
AU2007265181B2 (en) 2010-11-25
AR061623A1 (es) 2008-09-10
PT2046723E (pt) 2012-09-20
PE20080213A1 (es) 2008-05-08
IL195958A (en) 2016-09-29
EP2046723A2 (en) 2009-04-15
RU2009102271A (ru) 2010-08-10
JP5258761B2 (ja) 2013-08-07
AR108389A2 (es) 2018-08-15
TW200817309A (en) 2008-04-16
WO2008002853A3 (en) 2008-02-07
CA2655676C (en) 2014-07-22
US8362294B2 (en) 2013-01-29
CR10506A (es) 2009-02-02
MX2008016337A (es) 2009-01-16
IL195958A0 (en) 2009-09-22
EP2046723B1 (en) 2012-07-18
BRPI0713523A2 (pt) 2012-02-14
KR20090025366A (ko) 2009-03-10
PL2046723T3 (pl) 2012-12-31
ECSP088988A (es) 2009-01-30
MY145122A (en) 2011-12-30
ES2386989T3 (es) 2012-09-10
CN101479231A (zh) 2009-07-08
AU2007265181A1 (en) 2008-01-03
US20140058129A1 (en) 2014-02-27
GT200800296A (es) 2009-03-19
CL2007001857A1 (es) 2008-06-13
US8586782B2 (en) 2013-11-19
ZA200810562B (en) 2009-11-25
RU2454402C2 (ru) 2012-06-27
US20130012585A1 (en) 2013-01-10
JP2009541487A (ja) 2009-11-26
US20090209648A1 (en) 2009-08-20
MA30567B1 (fr) 2009-07-01
BRPI0713523A8 (pt) 2018-05-02

Similar Documents

Publication Publication Date Title
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
MX2009012595A (es) Derivados de espiroindolinona.
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
NO20090052L (no) Nye forbindelser
NO20083726L (no) Spiroindolinon derivater
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
IL192690A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
DK1778673T3 (da) Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application